Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Completed
National Cancer Institute (NCI)
Phase 2
2001-03-01
RATIONALE: Monoclonal antibodies, such as gemtuzumab ozogamicin, can locate cancer cells and
either kill them or deliver cancer-killing substances to them without harming normal cells.
Drugs used in chemotherapy, such as cytarabine, use different ways to stop cancer cells from
dividing so they stop growing or die. Combining gemtuzumab ozogamicin with cytarabine may
kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combining gemtuzumab ozogamicin with
high-dose cytarabine in treating patients who have relapsed or refractory acute myeloid
leukemia.
Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Completed
Alliance for Clinical Trials in Oncology
Phase 2
2001-03-01
RATIONALE: Monoclonal antibodies, such as gemtuzumab ozogamicin, can locate cancer cells and
either kill them or deliver cancer-killing substances to them without harming normal cells.
Drugs used in chemotherapy, such as cytarabine, use different ways to stop cancer cells from
dividing so they stop growing or die. Combining gemtuzumab ozogamicin with cytarabine may
kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combining gemtuzumab ozogamicin with
high-dose cytarabine in treating patients who have relapsed or refractory acute myeloid
leukemia.
Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia
Completed
Genta Incorporated
Phase 2
2000-12-01
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate tumor cells and
either kill them or deliver tumor-killing substances to them without harming normal cells.
Oblimersen may help gemtuzumab ozogamicin kill more cancer cells by making cancer cells more
sensitive to the drug.
PURPOSE: Phase II trial to study the effectiveness of combining oblimersen and gemtuzumab
ozogamicin in treating older patients who have relapsed acute myeloid leukemia.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
